- Home
- EXFY vs RIGL Comparison
EXFY vs RIGL Comparison
Compare EXFY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- RIGL
- Stock Information
- Founded
- EXFY 2008
- RIGL 1996
- Country
- EXFY United States
- RIGL United States
- Employees
- EXFY N/A
- RIGL N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- RIGL Health Care
- Exchange
- EXFY Nasdaq
- RIGL Nasdaq
- Market Cap
- EXFY 309.9M
- RIGL 298.0M
- IPO Year
- EXFY 2021
- RIGL 2000
- Fundamental
- Price
- EXFY $2.78
- RIGL $16.85
- Analyst Decision
- EXFY Buy
- RIGL Buy
- Analyst Count
- EXFY 4
- RIGL 5
- Target Price
- EXFY $5.00
- RIGL $36.80
- AVG Volume (30 Days)
- EXFY 338.3K
- RIGL 248.5K
- Earning Date
- EXFY 05-08-2025
- RIGL 05-06-2025
- Dividend Yield
- EXFY N/A
- RIGL N/A
- EPS Growth
- EXFY N/A
- RIGL N/A
- EPS
- EXFY N/A
- RIGL 0.99
- Revenue
- EXFY $139,236,000.00
- RIGL $179,278,000.00
- Revenue This Year
- EXFY $9.56
- RIGL $12.53
- Revenue Next Year
- EXFY $6.86
- RIGL $15.68
- P/E Ratio
- EXFY N/A
- RIGL $17.02
- Revenue Growth
- EXFY N/A
- RIGL 54.71
- 52 Week Low
- EXFY $1.24
- RIGL $7.48
- 52 Week High
- EXFY $4.13
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- EXFY 42.68
- RIGL 41.36
- Support Level
- EXFY $2.65
- RIGL $16.05
- Resistance Level
- EXFY $2.87
- RIGL $17.67
- Average True Range (ATR)
- EXFY 0.21
- RIGL 1.31
- MACD
- EXFY 0.01
- RIGL 0.02
- Stochastic Oscillator
- EXFY 47.62
- RIGL 45.76
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.